Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024003399> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W2024003399 endingPage "139" @default.
- W2024003399 startingPage "135" @default.
- W2024003399 abstract "1. The pharmacokinetics and tolerability of a new nonsteroidal anti-inflammatory drug (NSAID), meloxicam, administered i.m., were investigated in two studies conducted in healthy male volunteers. Study 1 was an open, placebo-controlled design in which 32 volunteers were randomized to a single ascending i.m. dose of meloxicam (5, 10, 20, and 30 mg) or placebo. Study 2 had an open, randomized two way crossover design in which 12 volunteers received single i.m. and i.v. doses of meloxicam (15 mg). 2. Meloxicam showed an excellent tolerability in both studies. No effect was seen on serum creatinphosphokinase (CK, the isoenzyme of the skeletal muscle enzyme, CK-MM, was determined). 3. Following i.m. administration meloxicam was rapidly and completely absorbed (mean absolute bioavailability 102%). Dose-proportionality was demonstrated with respect to Cmax (maximum plasma concentration) and AUC (extrapolated area under the plasma concentration-time curve from zero time to infinity) over a range of 5-30 mg. 4. Intravenous administration of meloxicam (15 mg) resulted in higher initial plasma concentrations (C3min, i.e. concentration in plasma 3 min after start of injection = 2.99 +/- 0.75 microgram.ml-1) than after i.m. injection (Cmax: 1.62 +/- 0.20 mg ml-1). All other pharmacokinetic parameters were similar for both routes of administration (apparent elimination half-life = 15-22 h; plasma clearance = 7-9 ml min-1). 5. In conclusion, the excellent tolerability of i.m. meloxicam together with its rapid and complete absorption may provide an alternative to oral administration of this drug." @default.
- W2024003399 created "2016-06-24" @default.
- W2024003399 creator A5004615988 @default.
- W2024003399 creator A5047919361 @default.
- W2024003399 creator A5057905093 @default.
- W2024003399 creator A5068153769 @default.
- W2024003399 creator A5081815145 @default.
- W2024003399 date "1996-02-01" @default.
- W2024003399 modified "2023-09-26" @default.
- W2024003399 title "Pharmacokinetics and tolerability of meloxicam after i.m. administration" @default.
- W2024003399 cites W1994977169 @default.
- W2024003399 cites W2010364706 @default.
- W2024003399 cites W2094425330 @default.
- W2024003399 cites W2171271116 @default.
- W2024003399 doi "https://doi.org/10.1111/j.1365-2125.1996.tb00171.x" @default.
- W2024003399 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8838440" @default.
- W2024003399 hasPublicationYear "1996" @default.
- W2024003399 type Work @default.
- W2024003399 sameAs 2024003399 @default.
- W2024003399 citedByCount "27" @default.
- W2024003399 countsByYear W20240033992013 @default.
- W2024003399 countsByYear W20240033992014 @default.
- W2024003399 countsByYear W20240033992016 @default.
- W2024003399 countsByYear W20240033992019 @default.
- W2024003399 countsByYear W20240033992020 @default.
- W2024003399 countsByYear W20240033992022 @default.
- W2024003399 crossrefType "journal-article" @default.
- W2024003399 hasAuthorship W2024003399A5004615988 @default.
- W2024003399 hasAuthorship W2024003399A5047919361 @default.
- W2024003399 hasAuthorship W2024003399A5057905093 @default.
- W2024003399 hasAuthorship W2024003399A5068153769 @default.
- W2024003399 hasAuthorship W2024003399A5081815145 @default.
- W2024003399 hasBestOaLocation W20240033991 @default.
- W2024003399 hasConcept C112705442 @default.
- W2024003399 hasConcept C142724271 @default.
- W2024003399 hasConcept C181389837 @default.
- W2024003399 hasConcept C185592680 @default.
- W2024003399 hasConcept C197934379 @default.
- W2024003399 hasConcept C204787440 @default.
- W2024003399 hasConcept C22979827 @default.
- W2024003399 hasConcept C27081682 @default.
- W2024003399 hasConcept C2778375690 @default.
- W2024003399 hasConcept C2779751750 @default.
- W2024003399 hasConcept C42219234 @default.
- W2024003399 hasConcept C71924100 @default.
- W2024003399 hasConcept C76318530 @default.
- W2024003399 hasConcept C87813604 @default.
- W2024003399 hasConcept C98274493 @default.
- W2024003399 hasConceptScore W2024003399C112705442 @default.
- W2024003399 hasConceptScore W2024003399C142724271 @default.
- W2024003399 hasConceptScore W2024003399C181389837 @default.
- W2024003399 hasConceptScore W2024003399C185592680 @default.
- W2024003399 hasConceptScore W2024003399C197934379 @default.
- W2024003399 hasConceptScore W2024003399C204787440 @default.
- W2024003399 hasConceptScore W2024003399C22979827 @default.
- W2024003399 hasConceptScore W2024003399C27081682 @default.
- W2024003399 hasConceptScore W2024003399C2778375690 @default.
- W2024003399 hasConceptScore W2024003399C2779751750 @default.
- W2024003399 hasConceptScore W2024003399C42219234 @default.
- W2024003399 hasConceptScore W2024003399C71924100 @default.
- W2024003399 hasConceptScore W2024003399C76318530 @default.
- W2024003399 hasConceptScore W2024003399C87813604 @default.
- W2024003399 hasConceptScore W2024003399C98274493 @default.
- W2024003399 hasIssue "2" @default.
- W2024003399 hasLocation W20240033991 @default.
- W2024003399 hasLocation W20240033992 @default.
- W2024003399 hasOpenAccess W2024003399 @default.
- W2024003399 hasPrimaryLocation W20240033991 @default.
- W2024003399 hasRelatedWork W1969574919 @default.
- W2024003399 hasRelatedWork W1984317973 @default.
- W2024003399 hasRelatedWork W2014270163 @default.
- W2024003399 hasRelatedWork W2068318921 @default.
- W2024003399 hasRelatedWork W2080955156 @default.
- W2024003399 hasRelatedWork W2355468301 @default.
- W2024003399 hasRelatedWork W2373237830 @default.
- W2024003399 hasRelatedWork W2374069256 @default.
- W2024003399 hasRelatedWork W3092052599 @default.
- W2024003399 hasRelatedWork W3146022116 @default.
- W2024003399 hasVolume "41" @default.
- W2024003399 isParatext "false" @default.
- W2024003399 isRetracted "false" @default.
- W2024003399 magId "2024003399" @default.
- W2024003399 workType "article" @default.